Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK1 NSCLC: Updated results from the phase III ALTA-1L trial
Authors
Camidge, RKim, HR
Ahn, MJ
Yang, JCH
Han, JY
Hochmair, MJ
Lee, KH
Delmonte, A
Campelo, MRG
Kim, DW
Griesinger, F
Felip, E
Califano, Raffaele
Spira, A
Gettinger, S
Tiseo, M
Ni, Q
Zhang, P
Popat, S
Affiliation
Medical Oncology, University of Colorado Cancer Center, 80045 - Aurora/USIssue Date
2019
Metadata
Show full item recordCitation
Camidge R, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial. Annals of Oncology. 2019;30:ix195-ix6.Journal
Annals of OncologyDOI
10.1093/annonc/mdz446Additional Links
https://dx.doi.org/10.1093/annonc/mdz446Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz446